A Controlled Trial of Long-Term Inhaled Hypertonic Saline in Patients with Cystic Fibrosis
Top Cited Papers
- 19 January 2006
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 354 (3), 229-240
- https://doi.org/10.1056/nejmoa043900
Abstract
Inhaled hypertonic saline acutely increases mucociliary clearance and, in short-term trials, improves lung function in people with cystic fibrosis. We tested the safety and efficacy of inhaled hypertonic saline in a long-term trial. In this double-blind, parallel-group trial, 164 patients with stable cystic fibrosis who were at least six years old were randomly assigned to inhale 4 ml of either 7 percent hypertonic saline or 0.9 percent (control) saline twice daily for 48 weeks, with quinine sulfate (0.25 mg per milliliter) added to each solution to mask the taste. A bronchodilator was given before each dose, and other standard therapies were continued during the trial. The primary outcome measure, the rate of change (slope) in lung function (reflected by the forced vital capacity [FVC], forced expiratory volume in one second [FEV1], and forced expiratory flow at 25 to 75 percent of FVC [FEF25–75]) during the 48 weeks of treatment, did not differ significantly between groups (P=0.79). However, the absolute difference in lung function between groups was significant (P=0.03) when averaged across all post-randomization visits in the 48-week treatment period. As compared with the control group, the hypertonic-saline group had significantly higher FVC (by 82 ml; 95 percent confidence interval, 12 to 153) and FEV1 (by 68 ml; 95 percent confidence interval, 3 to 132) values, but similar FEF25–75 values. The hypertonic-saline group also had significantly fewer pulmonary exacerbations (relative reduction, 56 percent; P=0.02) and a significantly higher percentage of patients without exacerbations (76 percent, as compared with 62 percent in the control group; P=0.03). Hypertonic saline was not associated with worsening bacterial infection or inflammation. Hypertonic saline preceded by a bronchodilator is an inexpensive, safe, and effective additional therapy for patients with cystic fibrosis. (ClinicalTrials.gov number, NCT00271310.)Keywords
This publication has 26 references indexed in Scilit:
- Lung Inflammation as a Therapeutic Target in Cystic FibrosisAmerican Journal of Respiratory Cell and Molecular Biology, 2004
- Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosisThorax, 2002
- The CF Salt ControversyMolecular Cell, 2001
- DNase use in the daily care of cystic fibrosis: who benefits from it and to what extent? Results of a cohort study of 199 patients in 13 centresEuropean Journal of Pediatrics, 2000
- Intermittent Administration of Inhaled Tobramycin in Patients with Cystic FibrosisNew England Journal of Medicine, 1999
- Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea.JCI Insight, 1997
- Cystic Fibrosis Airway Epithelia Fail to Kill Bacteria Because of Abnormal Airway Surface FluidCell, 1996
- Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic FibrosisNew England Journal of Medicine, 1994
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- Selective media for the quantitation of bacteria in cystic fibrosis sputumJournal of Medical Microbiology, 1984